- Policy
- The mechanism by SGLT2 inhibitors was first identified
- by Lee, Hye-Kyung May 18, 2020 06:15am
- Research has shown that the 'diabetes treatment agent' SGLT2 inhibitor lowers the risk of cardiovascular disease by inhibiting inflammatory cytokine secretion. Jung-Sun Kim, Professor of cardiology, Yong-ho Lee Professor of endocrinology, and Sang-Guk Lee Professor of laboratory medicine at Severance Hospital and So Ra Kim, Professor of hosp
- Policy
- Patients suffer from quarrels between companies & the HIRA
- by Lee, Jeong-Hwan May 18, 2020 06:15am
- Patients urged Ono Pharma Korea, BMS Korea, and MSD Korea to come up with a reasonable burden-sharing plan that the health authorities could accept. Patients have been urging to expand the health benefits of Opdivo (Nivolumab) and Keytruda (Pembrolizumab), which have various therapeutic indications, such as lung cancer and kidney cancer.
- Policy
- Xeljanz was rejected for the uninsured benefit
- by Lee, Hye-Kyung May 18, 2020 06:14am
- The application to use 'Xeljanz (Tofacitinib citrate)' from Pfizer Korea, which has been approved for rheumatoid arthritis and ulcerative colitis, was rejected for the uninsured benefit for patients with dermatomyositis or severe alopecia. The HIRA is applying in advance for the uninsured benefit that is not approved by the MFDS in orde
- Policy
- Korea takes two-track approach on vaccine and treatment
- by Kim, Jung-Ju May 15, 2020 06:04am
- To speed up the development of Korean-made COVID-19 vaccine and treatment, the Korean government is swiftly working two most urgent regulatory changes. The revised regulation would stipulate Korean Red Cross, a non-healthcare institute, to collect blood samples integral for convalescent plasma therapy, and grant private companies to access biosa
- Policy
- HIRA, promote 'COVID-19' outcome at OECD
- by Lee, Hye-Kyung May 14, 2020 02:21pm
- The meeting of the Working Party on Healthcare Quality and Outcomes (HCQO) of Organisation for Economic Co-operation and Development (OECD) was held on 12 May 2020, chaired by Dr. Sun Min Kim, president of Health Insurance Review and Assessment Service (HIRA) of Korea. OECD HCQO was started in 2001 to develop, collect, and compare a set
- Policy
- Issues on e-cigarette·NDMA were raised again
- by Choi sun May 14, 2020 06:25am
- Issues related to medicines that were quiet due to the COVID-19 outbreak were raised again. There are big issues waiting to be investigated, from sampling investigations of Metformin to conducting work on overseas manufacturing plants and publishing results of risk studies of electronic cigarettes. According to the MFDS on the 13th, it recent
- Policy
- Exports of the health industry in April rose 20%
- by Lee, Tak-Sun May 14, 2020 06:24am
- As the export of diagnostic reagents and disinfectants increased in the aftermath of COVID-19, the export amount of the health industry increased by more than 20% from the same period last year. The KHIDI (Korea Health Industry Development institute (Director Kwon Deok-cheol) announced monthly health industry export performance. In April, exp
- Policy
- KAPO demands MFDS to swiftly approve Lutathera
- by Lee, Jeong-Hwan May 13, 2020 05:54am
- A patient group once again urged for a prompt approval review on neuroendocrine tumor treatment Lutathera (lutetium Lu 177 dotatate). The group demanded the Korean government to take action fast for the patients with neuroendocrine tumor in agony with inevitable overseas treatment and burdensome pharmaceutical expense amid COVID-19 pande
- Policy
- Whanin, begins development of first generic for Fycompa
- by Lee, Tak-Sun May 13, 2020 05:54am
- Whanin, for the first time as a domestic pharmaceutical company, started developing generics for antiepileptic drug Fycompa by Eisai. If the generic development proceeds smoothly, it is expected that it will be aprproved next year as soon as possible. The MFDS approved the bioequivalence test plan for 'Peranel 6mg' submitted by Whanin on t
- Policy
- Chong Kun Dang to enhance Eliquis generic quality
- by Lee, Tak-Sun May 12, 2020 06:27am
- Chong Kun Dang is to enhance quality of Liquisia, a generic version of coagulant medicine Eliquis. Currently leading the Eliquis generic market, Liquisia is aiming for sales expansion through the substance quality improvement. On Apr. 29, Ministry of Food and Drug Safety (MFDS) approved of bioequivalence test plan for Liquisia (apixaban)
